Form D · Other
Cercacor Laboratories, Inc.
Irvine, CA · CIK 0001061031
Offering snapshot reported Dec 1, 2017 · SEC filing
- Reported sold
- $4.89M Offering amount: $4.89M
- Investors reported
- 58 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 12, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 1, 2017 | Initial | $4,894,140 | No comparison | 58 | SEC filing |
| Dec 8, 2016 | Initial | $1,000,000 | No comparison | 46 | SEC filing |
| Jul 25, 2016 | Initial | $2,000,000 | No comparison | 51 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-299876
Source: Form D, filed Dec 1, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mohamed Diab | Director |
| Germain E. Hammarth | Executive |
| Stephen Jensen | Director |
| Mark B. Kessenbaum | Director |
| Joe E. Kiani | Director, Executive |
| Abraham M. Kiani | Director |
| Parag Saxena | Director |
Issuer details
Industry: Other (See others in industry)
Address:
40 Parker Drive
Irvine, CA, 92618
Irvine, CA, 92618